A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma

<div>(a): LUAD clinicopathological variables under different hypoxia scores. (b): The Kaplan–Meier survival curve of distinct hypoxia score group. (c): Univariate (left) and multivariate Cox regression analysis (right) of hypoxia and LUAD clinical variables. (d): The evaluation of hypoxia score was grouped according to different clinical variables (age, gender, status, T stage, N stage, M stage, and AJCC stage) of LUAD.</div>

Journal of Oncology

fig1

Figure 1

Figure 1: A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma 

Figure 1 | A New Hypoxia-Related Prognostic Risk Score (HPRS) Model Was Developed to Indicate Prognosis and Response to Immunotherapy for Lung Adenocarcinoma 